A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
PHASE1CompletedINTERVENTIONAL
Enrollment
25
Participants
Timeline
Start Date
March 15, 2013
Primary Completion Date
July 17, 2013
Study Completion Date
July 17, 2013
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG
MK-8892
DRUG
Placebo for MK-8892
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01798849 - A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001) | Biotech Hunter | Biotech Hunter